The use of topical aqueous suppressants in the prevention of postoperative intraocular pressure elevation after pars plana vitrectomy with long-acting gas tamponade.
OBJECTIVE
To determine whether topical aqueous suppressant therapy applied after pars plana vitrectomy with gas tamponade prevents postoperative intraocular pressure (IOP) elevation.


METHODS
Prospective, nonrandomized comparative study.


METHODS
Forty-one patients who met inclusion criteria and underwent pars plana vitrectomy with gas tamponade (SF6 18%-20% or C3F8 12%-16%) over a 1-year period.


METHODS
Treatment eyes received topical aqueous suppressants at the end of surgery.


METHODS
Postoperative IOP at 4 to 6 hours, 1 day, and 1 week.


RESULTS
Twenty-one control and 20 treatment eyes met the inclusion criteria. The IOP (in mmHg) measured at 4 to 6 hours (23.05 [control, 14.73 [treatment]) and 1 day (23.24 [control], 17.28 [treatment]) postoperatively showed a statistically significant difference between the groups (P = 0.0038) at 4 to 6 hours and a trend toward significance (P = 0.057) at 1 day. Eleven control and three treatment eyes had an IOP spike above 25 mmHg at 4 to 6 hours or 1 day postoperatively (P = 0.02), and six control eyes and one treatment eye had postoperative IOP greater than 30 mmHg. A pressure rise greater than 40 mmHg was seen in two control eyes and no treatment eyes.


CONCLUSIONS
Use of topical aqueous suppressants after pars plana vitrectomy with long-acting gas tamponade is effective in preventing significant postoperative IOP elevation in most cases.
Mittra
R A
RA
Vitreoretinal Section of the Eye Institute, Medical College of Wisconsin, Milwaukee, USA.
Pollack
J S
JS
Dev
S
S
Han
D P
DP
Mieler
W F
WF
Pulido
J S
JS
Connor
T B
TB
D000287:Administration, Topical; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001082:Aqueous Humor / Q000187:drug effects*; D000068438:Brimonidine Tartrate; D003000:Clonidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D005466:Fluorocarbons / Q000008:administration & dosage*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D009798:Ocular Hypertension / Q000209:etiology / Q000517:prevention & control*; D011446:Prospective Studies; D011810:Quinoxalines / Q000008:administration & dosage / Q000627:therapeutic use; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use; D013459:Sulfur Hexafluoride / Q000008:administration & dosage*; D013876:Thiophenes / Q000008:administration & dosage / Q000627:therapeutic use; D013999:Timolol / Q000008:administration & dosage / Q000627:therapeutic use; D014821:Vitrectomy / Q000009:adverse effects*
D000959:Antihypertensive Agents; D005466:Fluorocarbons; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000068438:Brimonidine Tartrate; D013999:Timolol; C016986:apraclonidine; C062765:dorzolamide; C042852:perflutren; D003000:Clonidine; D013459:Sulfur Hexafluoride